Holen Sie sich die Stockscreener-App
2.25
5.77%
0.17
Handel nachbörslich:
2.24
-0.010
-0.44%
Schlusskurs vom Vortag:
$2.08
Offen:
$2.08
24-Stunden-Volumen:
175.74K
Relative Volume:
1.19
Marktkapitalisierung:
$4.82M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.98M
KGV:
-0.2566
EPS:
-8.7693
Netto-Cashflow:
$-6.49M
1W Leistung:
+6.80%
1M Leistung:
+39.24%
6M Leistung:
-71.61%
1J Leistung:
-87.24%
1-Tages-Spanne:
$1.9501
$2.28
1-Wochen-Bereich:
$1.94
$2.39
52-Wochen-Spanne:
$1.31
$18.90
Adial Pharmaceuticals Inc Stock (ADIL) Company Profile
Firmenname
Adial Pharmaceuticals Inc
Sektor
Branche
Telefon
434-422-9800
Adresse
1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
Compare ADIL vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADIL
Adial Pharmaceuticals Inc
|
2.25 | 4.46M | 0 | -7.98M | -6.49M | -8.7693 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Adial Pharmaceuticals Inc Stock (ADIL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-14 | Eingeleitet | Rodman & Renshaw | Buy |
| 2018-10-30 | Eingeleitet | Maxim Group | Buy |
| 2018-10-11 | Eingeleitet | Dawson James | Buy |
Adial Pharmaceuticals Inc Aktie (ADIL) Neueste Nachrichten
Adial Pharmaceuticals Stock Faces Crucial AD04 Funding Test After Holiday Break - Bez Kabli
Adial Pharmaceuticals (ADIL) Drops 9.57% as Selling Pressure Mounts Near Key SupportShakeout Pattern - Newser
ADIL Q1 2026 Earnings: Narrowed Loss Beats Estimates, but Market Remains CautiousSocial Flow Trades - Newser
ADIL Q1 2026 Earnings: Narrowing Loss Beats Estimates, But Stock Declines Amid No RevenuePost-Earnings Reaction - Newser
Adial Pharmaceuticals lead drug fits new policy mood as bipartisan bill signals broader lens on alcohol use disorder - MSN
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Why Is Adial Pharmaceuticals, Inc. (ADIL) Stock Down Today? - Meyka
Why Is Adial Pharmaceuticals, Inc. WT EXP 073123 (ADILW) Stock Up Today? - Meyka
Armistice Capital/Steven Boyd report 4.99% stake in Adial (NASDAQ: ADIL) - Stock Titan
ADIL Should I Buy - Intellectia AI
Maxim Group Maintains Adial Pharmaceuticals(ADIL.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Adial Pharmaceuticals 1Q Loss $2M >ADIL - Moomoo
The quiet strength in Adial Pharma (ADIL) business model (+4.20%) 2026-05-11Community Chart Signals - Newser
Adial Pharmaceuticals: Runway to Fund Operating Expenses Into 2nd Half of 2026 >ADIL - Moomoo
Adial Pharmaceuticals Q1 Net Income USD2 Million - TradingView
Adial Pharmaceuticals Reports Q1 2026 Results, Advances AD04 for Alcohol Use Disorder with FDA and European Developments 12 - Minichart
Adial Pharmaceuticals (NASDAQ: ADIL) details evolving AD04 development and IP - Stock Titan
Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update - ChartMill
Adial Pharmaceuticals Q1 2026 10-Q Report: Clinical Development of AD04 for Alcohol Use Disorder, Financial Results, and Liquidity Update - Minichart
Adial Pharmaceuticals Inc (ADIL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Adial Pharmaceuticals Inc expected to post a loss of $1.21 a shareEarnings Preview - TradingView
Adial Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Adial (NASDAQ: ADIL) flags going concern risk while advancing AD04 partnership plans - Stock Titan
ADIL Price Today: Adial Pharmaceuticals, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
The quiet positioning of Adial Pharma (ADIL) nobody discusses (-10.13%) 2026-05-08Value ETF - Newser
EBIT per share of Adial Pharmaceuticals, Inc – NASDAQ:ADIL - TradingView
ADIL Stock Price, Quote & Chart | ADIAL PHARMACEUTICALS INC (NASDAQ:ADIL) - ChartMill
Adial Pharmaceuticals files patent application for AD04 By Investing.com - Investing.com South Africa
Adial Pharmaceuticals files patent application for AD04 - Investing.com
Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045 - The Manila Times
Adial seeks U.S. patent that could protect its lead alcohol-use drug to 2045 - Stock Titan
Adial Pharmaceuticals Files New U.S. Utility Patent Application For AD04 Targeting Alcohol Use Disorder - marketscreener.com
Exclusive: Adial Pharmaceuticals clears manufacturing milestone ahead of pivotal study for alcohol use disorder drug - MSN
Why did Adial Pharmaceuticals stock plunge over 20% after hours today? - MSN
Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight - GlobeNewswire Inc.
Adial Pharmaceuticals (ADIL) Submits Application to FDA's National Priority Voucher Program - GuruFocus
Adial Pharmaceuticals applies for FDA priority voucher program - Investing.com
Adial Pharmaceuticals applies for FDA priority voucher program By Investing.com - Investing.com India
Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program - The Manila Times
Adial Pharmaceuticals (ADIL) price target decreased by 10.26% to 23.80 - MSN
EXCLUSIVE: Adial Pharmaceuticals Clears Manufacturing Milestone Ahead Of Pivotal Study For Alcohol Use Disorder Drug - Sahm
Adial Pharmaceuticals completes AD04 demonstration batch production By Investing.com - Investing.com Australia
ADIL (Adial Pharmaceuticals Inc) reports wider than expected Q4 2025 loss, yet stock notches 2.53 percent gain today.Quick Ratio - UBND thành phố Hải Phòng
Finanzdaten der Adial Pharmaceuticals Inc-Aktie (ADIL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):